ORLANDO -- The investigational interleukin (IL)-6 inhibitor vamikibart led to visual improvements in uveitic macular edema in two identical phase III trials, with one exception.

Solana (SOL) has dropped 22% this month amid Trump’s tariff shock, but signs of recovery are emerging. The token bounced off ...

Have you ever wondered why flying an airplane requires certification while practicing fundamental and technical analysis does ...

Elevance Health, Inc. ( NYSE: ELV) Q3 2025 Earnings Call October 21, 2025 8:30 AM EDT Ladies and gentlemen, thank you for standing by, and welcome to the Elevance Health Third Quarter Earnings ...

CStone Pharmaceuticals ( OTCPK:CSPHF) Discusses CS2009 Data Interpretation and Future Clinical Development Strategy October 20, 2025 9:00 AM EDT ...

This valuable study addresses the effects of selection on aggression on fitness and life-history trade-offs in Drosophila melanogaster. However, the evidence presented is incomplete and does not ...

Two-dimensional (2D) materials, which are only a few atoms thick, are known to exhibit unique electrical, mechanical and ...

AFFIRM-1 trial did not meet primary endpoint or secondary endpoints Company to conduct strategic review of portfolio and business operations BURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Neupho ...

Neuromod, the medical device company that created the Lenire tinnitus treatment device, has launched Tinnitus Masterclass, an online course that provides hearing care professionals with expert ...

Introduction Polypharmacy in older adults is a growing concern, particularly in general practice (GP), where general practitioners (GPs) are the main prescribers managing complex multimorbidity. While ...